[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525537":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":29,"responsibleParty":50,"collaborators":25,"id":52,"slug":25,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":25,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":25,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":25,"overallStatus":32,"whyStopped":25,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Northwestern University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cabergoline","EXPERIMENTAL","1mg oral cabergoline administered once after patient's procedure",[13],"Drug: Cabergoline",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","1 tablet encapsulated placebo by Investigational Drug Pharmacy administered once after patient's procedure",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","1mg oral cabergoline given to participants once",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"1 encapsulated placebo tablet given to participants after procedure",[15],[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Northwestern Medical Center","RECRUITING","Chicago","Illinois","60611","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-87.65005,41.85003,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":25,"email":49},"Leanne McCloskey","CONTACT","312-926-8678","erin.fleurant@nm.org",{"type":51,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100525537",false,"NCT06123026","Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion","Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion: a Randomized Controlled Trial","Inclusion Criteria:\n\n* pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises\n* ages 18 to 50\n* con provide informed consent in English\n\nExclusion Criteria:\n\n* Age under 18 or above 50\n* gestational ages before 16 weeks 0 days or after 20 weeks 0 days\n* unable to provide written consent in English\n* hypertensive disorder\n* uncontrolled hypertension or known hypersensitivity to ergot derivatives\n* History of cardiac valvular disorders\n* history of pulmonary fibrosis\n* documented bipolar schizophrenia\n* documented allergy to medication, including lactose intolerance (placebo pill involves lactose)",true,"FEMALE","18 Years","50 Years",{"count":63,"type":64},200,"ESTIMATED","INTERVENTIONAL",[67],"PHASE4","The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called \"cabergoline\" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.",[70,71],"Lactation Suppressed","Second Trimester Abortion","2024-05-28",{"date":74,"type":75},"2024-05-29","ACTUAL",{"date":77,"type":75},"2023-12-18",{"date":79,"type":64},"2024-06-30",{"name":5,"class":6},1]